LUP.F Luye Pharma Group Ltd

Healthcare Pharmaceuticals Frankfurt Exchange
0.1817 EUR
Close of Nov 13, 2026
0.1780 0.3420
Market cap
EUR 726M
P/E
17.9x
P/B
0.36x
ROE
3.8%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is LUP.F undervalued?

Graham number
Price0.1817
Graham value0.3381
Discount46.3%

LUP.F trades 46.3% below its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Luye Pharma Group Ltd fundamental analysis

No fundamental analysis for Luye Pharma Group Ltd yet.

Luye Pharma Group Ltd stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Luye Pharma Group Ltd

Luye Pharma Group Ltd., together with its subsidiaries, develops, produces, markets, and sells pharmaceutical products in the People's Republic of China, the United States, Europe, and internationally. The company offers Lipusu, for ovarian cancer and carcinoma of ovary; CMNa, a chemical sensitizer for cancer radiotherapy; Boyounuo, an injection for the treatment of various types of cancers; and Xuezhikang, a lipid-regulating drug for the treatment of hypercholesterolaemia. …

Full company profile